Bronchitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Bronchitis – Pipeline Review, H2 2016’, provides an overview of the Bronchitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bronchitis

The report reviews pipeline therapeutics for Bronchitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bronchitis therapeutics and enlists all their major and minor projects

The report assesses Bronchitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bronchitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bronchitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AstraZeneca Plc

DBV Technologies S.A.

F. Hoffmann-La Roche Ltd.

Hyundai Pharmaceutical Co., Ltd.

Invion Limited

Kyorin Pharmaceutical Co., Ltd.

Mucosis B.V.

Orbis Biosciences Inc

Recipharm AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Bronchitis Overview 7

Therapeutics Development 8

Pipeline Products for Bronchitis - Overview 8

Bronchitis - Therapeutics under Development by Companies 9

Bronchitis - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Bronchitis - Products under Development by Companies 13

Bronchitis - Companies Involved in Therapeutics Development 14

AstraZeneca Plc 14

DBV Technologies S.A. 15

F. Hoffmann-La Roche Ltd. 16

Hyundai Pharmaceutical Co., Ltd. 17

Invion Limited 18

Kyorin Pharmaceutical Co., Ltd. 19

Mucosis B.V. 20

Orbis Biosciences Inc 21

Recipharm AB 22

Bronchitis - Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

alteplase - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

AZD-9668 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

erdosteine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

HOB-051 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

KRPAM-1977X - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

nadolol - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

nitric oxide - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

prednisone - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

respiratory syncytial virus vaccine - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

SynGEM - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Bronchitis - Dormant Projects 50

Bronchitis - Discontinued Products 52

Bronchitis - Product Development Milestones 53

Featured News & Press Releases 53

Nov 10, 2015: Recipharm secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical 53

Nov 10, 2015: Recipharm secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical 53

Oct 07, 2015: EVP R&D Dr Mitchell Glass discusses with BRR media data from the Phase 2 clinical trial of INV102 (nadolol) in Smoking Cessation 54

Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 54

Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings 55

Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants 55

Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 56

Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine 56

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

List of Tables

Number of Products under Development for Bronchitis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Bronchitis – Pipeline by AstraZeneca Plc, H2 2016 14

Bronchitis – Pipeline by DBV Technologies S.A., H2 2016 15

Bronchitis – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 16

Bronchitis – Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 17

Bronchitis – Pipeline by Invion Limited, H2 2016 18

Bronchitis – Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 19

Bronchitis – Pipeline by Mucosis B.V., H2 2016 20

Bronchitis – Pipeline by Orbis Biosciences Inc, H2 2016 21

Bronchitis – Pipeline by Recipharm AB, H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Stage and Target, H2 2016 25

Number of Products by Stage and Mechanism of Action, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Bronchitis – Dormant Projects, H2 2016 50

Bronchitis – Dormant Projects (Contd..1), H2 2016 51

Bronchitis – Discontinued Products, H2 2016 52

List of Figures

List of Figures

Number of Products under Development for Bronchitis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Targets, H2 2016 24

Number of Products by Stage and Targets, H2 2016 24

Number of Products by Mechanism of Actions, H2 2016 26

Number of Products by Stage and Mechanism of Actions, H2 2016 26

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Types, H2 2016 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports